Cronos Group/$CRON
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cronos Group
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
Ticker
$CRON
Sector
Primary listing
Employees
459
Headquarters
Stayner, Canada
Website
Cronos Group Metrics
BasicAdvanced
$965M
52.44
$0.05
1.50
-
Price and volume
Market cap
$965M
Beta
1.5
52-week high
$2.77
52-week low
$1.60
Average daily volume
3.4M
Financial strength
Current ratio
24.65
Quick ratio
23.232
Long term debt to equity
0.105
Total debt to equity
0.178
Dividend payout ratio (TTM)
20.87%
Profitability
EBITDA (TTM)
-20.785
Gross margin (TTM)
36.80%
Net profit margin (TTM)
14.19%
Operating margin (TTM)
-25.66%
Effective tax rate (TTM)
-8.95%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-1.84%
Return on equity (TTM)
1.88%
Valuation
Price to earnings (TTM)
52.441
Price to revenue (TTM)
7.442
Price to book
1.24
Price to tangible book (TTM)
1.33
Price to free cash flow (TTM)
-103.005
Free cash flow yield (TTM)
-0.97%
Free cash flow per share (TTM)
-0.025
Growth
Revenue change (TTM)
28.01%
Earnings per share change (TTM)
-132.04%
3-year revenue growth (CAGR)
12.91%
10-year revenue growth (CAGR)
71.00%
3-year earnings per share growth (CAGR)
-45.30%
10-year earnings per share growth (CAGR)
-7.58%
What the Analysts think about Cronos Group
Analyst ratings (Buy, Hold, Sell) for Cronos Group stock.
Bulls say / Bears say
Cronos reported net revenue of $33.6 million for Q1 2025, a 33% year-over-year increase on a constant currency basis, driven by higher cannabis flower sales in Israel and other markets, as well as greater extract sales in Canada.
Adjusted gross profit increased 218% to $14.3 million, pushing adjusted gross margin up to 44% from 18%. This reflects improved production efficiency, better pricing, and lower direct costs.
The company maintained a strong liquidity position with cash and short-term investments totaling $838.1 million as of March 31, 2025, supporting continued expansion and strategic initiatives.
Regulatory uncertainty in Israel remains, as the Minister of Economy aims to enforce a possible 165% anti-dumping duty on Canadian medical cannabis despite a veto from the Minister of Finance. This could lead to higher costs and reduced market access.
Cronos' expansion into the U.S. market depends on federal legalization; with no clear timeline for lifting prohibition, the company cannot exercise its 5.9% PharmaCann acquisition option yet, limiting potential growth in the U.S.
Continued geopolitical instability in the Middle East could disrupt operations, supply chains, and patient demand in Israel. Israel is a crucial market, making up 29% of Q1 revenue.
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
Cronos Group Financial Performance
Revenues and expenses
Cronos Group Earnings Performance
Company profitability
Cronos Group News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cronos Group stock?
Cronos Group (CRON) has a market cap of $965M as of September 15, 2025.
What is the P/E ratio for Cronos Group stock?
The price to earnings (P/E) ratio for Cronos Group (CRON) stock is 52.44 as of September 15, 2025.
Does Cronos Group stock pay dividends?
No, Cronos Group (CRON) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Cronos Group dividend payment date?
Cronos Group (CRON) stock does not pay dividends to its shareholders.
What is the beta indicator for Cronos Group?
Cronos Group (CRON) has a beta rating of 1.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.